Pando Bio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Pando Bio - overview
Established
2013
Location
Shenzhen, Guangdong, China
Primary Industry
Biotechnology
About
Established in 2013 and based in Shenzhen, China, Pando Bio is a biotechnology company that focuses on the translational application of super early molecular detection technology in the field of disease screening and diagnosis. The company has cooperation with the National Genetic Institute, the Chinese Academy of Sciences, Peking University Sixth Hospital, and other institutions. In November 2015, the company raised CNY 50 million in angel funding. The company is committed to providing genetic consulting and remote medical services, which include immune function testing and single-molecule protein chip detection.
The immune function testing service can detect the status of innate and adaptive immune cells, evaluate the body's ability to resist infections and tumors and suggest the risk of immune disorders. The company generates revenue by providing genetic consulting and remote medical services.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Medical Software
Website
www.pandobio.com
Verticals
HealthTech, Mobile Apps
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.